Mitochondrial metabolism as a target for cancer therapy
K Vasan, M Werner, NS Chandel - Cell metabolism, 2020 - cell.com
Recent evidence in humans and mice supports the notion that mitochondrial metabolism is
active and necessary for tumor growth. Mitochondrial metabolism supports tumor anabolism …
active and necessary for tumor growth. Mitochondrial metabolism supports tumor anabolism …
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Drug resistance represents a major obstacle in cancer management, and the mechanisms
underlying stress adaptation of cancer cells in response to therapy-induced hostile …
underlying stress adaptation of cancer cells in response to therapy-induced hostile …
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Summary Background Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in
multiple B-cell malignancies, but patients discontinue these agents due to resistance and …
multiple B-cell malignancies, but patients discontinue these agents due to resistance and …
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
F Nadeu, R Royo, R Massoni-Badosa… - Nature medicine, 2022 - nature.com
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia
(CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The …
(CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The …
Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
T Wen, J Wang, Y Shi, H Qian, P Liu - Leukemia, 2021 - nature.com
Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
JL Carter, K Hege, J Yang, HA Kalpage, Y Su… - Signal transduction and …, 2020 - nature.com
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …
second most common form of acute leukemia in children. Despite this, very little …
Impairing Tumor Metabolic Plasticity via a Stable Metal‐Phenolic‐Based Polymeric Nanomedicine to Suppress Colorectal Cancer
Targeting metabolic vulnerability of tumor cells is a promising anticancer strategy. However,
the therapeutic efficacy of existing metabolism‐regulating agents is often compromised due …
the therapeutic efficacy of existing metabolism‐regulating agents is often compromised due …
Targeting janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution
U Bharadwaj, MM Kasembeli, P Robinson… - Pharmacological …, 2020 - Elsevier
Before it was molecularly cloned in 1994, acute-phase response factor or signal transducer
and activator of transcription (STAT) 3 was the focus of intense research into understanding …
and activator of transcription (STAT) 3 was the focus of intense research into understanding …
[HTML][HTML] Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications
Oxidative phosphorylation (OXPHOS) takes place in mitochondria and is the process
whereby cells use carbon fuels and oxygen to generate ATP. Formerly OXPHOS was …
whereby cells use carbon fuels and oxygen to generate ATP. Formerly OXPHOS was …